How Does Interleukin-22 Mediate Liver Regeneration and Prevent Injury and Fibrosis?

Interleukin-22 (IL-22) is a pluripotent T cell-derived cytokine which is a member of IL-10 cytokine family. It is the only interleukin produced by immune cells but does not target immune system components. IL-22 is mainly produced by dendritic cells (DCs) and TH17, TH22, NK, and NKT cells and targets a number of body tissues including liver, pancreas, and other epithelial tissues. It provokes a series of downstream signaling pathways upon binding with IL-22R complex which protects liver damage through STAT3 activation. IL-22BP is an inhibitor of IL-22 which has 20-1000x more affinity to bind with IL-22 compared to IL-22R1 that inhibits IL-22 activity. Its level was found to be positively correlated with the severity of liver damage and fibrosis. So, the present review is an effort to reveal the exact mechanism lying in the hepatoprotective activity of IL-22 and some of its future therapeutic implications.

Radiation Cross-linked Polyethylene Foam: Preparation and Properties

The ability of some additives to increase the efficiency of polyethylene (PE) cross-linking is studied. The results confirm that additives are effective especially at low doses. Formulations of radiation cross-linked PE foam are used, and optimum conditions for the foaming process to prepare desirable final products are obtained. In addition, different properties of the foam, such as tensile properties, density, water absorption, thermal conductivity, and cellular structure, are determined in relation to blowing agent concentration. Finally, a PE foam formula with desirable properties is introduced.

Counter effects of N. Sativa L. and P. ovate L. on indicative markers of non alcoholic fatty liver disease

The broad spectrum of non-alcoholic fatty liver disease (NAFLD) diseases ranges from simple liver inflammation to steatosis, leading to fibrosis and cirrhosis. Four groups of weaning (30g) Rattus norvegicus were designated as W-0, W-I, W-II and W-III. For sixteen weeks group W-0 was given standard pallet diet, group I consumed diet "A" (20% fat Sucrose + 33% tea whitener + 34% ground pallet diet +13% water), group W-II was fed on diet "B" (50g Nigella sativa seeds/kg of A) and group W-III was provided with diet "C" (50g Plantago ovata husks /Kg of A). The analysis of CBC, LFTs, and Lipid profile revealed that there were highly significant changes (P<0.001) in the MCV, PLT, Hb, MCH, MCHC, RBC, RDW%, WBC, MPV, Triglycerides, cholesterol, LDL and the significant alterations (P<0.01) in albumin, AST, bilirubin, AST/ALT, HDL and cholesterol/HDL were observed in the experimental groups when compared with control by using one way ANOVA. We concluded that high-energy diet can alter the blood profile. Moreover fat plummeting agents have counter impact on the hematology as well as serology of diet induced NAFLD in R. norvegicus.

Abstract 1313: Characterization and isolation of antigen-responding T cells in Sipuleucel-T treated patients

Sipuleucel-T is an FDA-approved autologous cellular therapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate (mCRPC). Sipuleucel-T is manufactured from peripheral blood mononuclear cells (PBMCs) cultured with PA2024, a fusion antigen composed of prostatic acid phosphatase (PAP) fused to granulocyte macrophage-colony stimulating factor (GM-CSF). We have demonstrated that following three infusions this therapy results in T cell antigen specific responses directed against both PA2024 and PAP in treated patients. In this study we utilized the cellular dye Carboxyfluorescein succinimidyl ester (CSFE) and flow cytometric analysis to further characterize antigen responding T cells in Sipuleucel-T treated patients. We observed that CD4+ T cells predominate the antigen-responding T cell population following treatment, confirming our previous studies. Importantly, this approach has allowed us to also visualize a previously undetected population of antigen responding CD8+ T cells. The frequency of both of these populations is enhanced following treatment relative to baseline responses and the responding T cells display increased surface expression of the prototypical T cell activation markers CD134 and CD137 relative to non-proliferating T cells. Additionally, we are exploiting the increased surface expression of these activation markers on antigen-responding T cells to isolate these cells in an HLA and epitope-independent manner. Using this methodology we have demonstrated Sipuleucel-T is capable of inducing both CD4+ and CD8+ antigen-specific T cell responses in treated patients, and that we are capable of isolating these antigen-responding T cells specifically and with minimal manipulation.

Citation Format: Jeff Pufnock, Tuyen Vu, James Trager, Nadeem Sheikh. Characterization and isolation of antigen-responding T cells in Sipuleucel-T treated patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1313. doi:10.1158/1538-7445.AM2015-1313

Pediatric Catheterization Protocol

During the last decade, significant technological progress has taken place in the pediatric cardiac catheterization laboratory. Improved noninvasive diagnostic techniques have narrowed down the indications for diagnostic cardiac catheterization, and these techniques are now increasingly being applied to therapeutic procedures. Recently, concern has been raised about the appropriateness of some these applications in pediatric therapeutic cardiac catheterization because of sheer increase in number of techniques being applied, the increase in the number of persons and centers using these techniques, and the increase in the number of lesion types thought to be amenable to catheter therapy. In comparison to diagnostic cardiac catheterization, therapeutic catheterization require more time and resources, involve higher cost and risk, and demand more technical competence and expertise. Higher level of skill and competency is requirement for the operator who performs the various therapeutic catheterization techniques. These procedures should only be performed in institutions equipped with appropriate facilities, personnel, and programs. These considerations, combined with the rapid increase in the number of laboratories and cardiologists performing therapeutic catheterization procedures, raises concern about the safety of patients and human subjects as well as credentials of hospital and level of training and skill of physician involved. Therapeutic catheterization training programs vary in type, extent, and quality. Due to the complexity and potential risks of these procedures, specific skill and competency benchmark should be developed for personnel undergoing training in therapeutic catheterization as well as for those who continue to perform various procedures. Competency in therapeutic catheterization in children requires specific training. Pediatric cardiology fellows should receive therapeutic catheterization training in one or more centers that specializes in angioplasties, valvuloplasties, and/or vascular occlusion procedures. Before performing a therapeutic catheterization as the primary operator, the fellow or practicing pediatric cardiologist should be required to receive procedure-specific training under the supervision of a qualified individual. Credential should be procedure specific. To maintain his or her credentials and skills, the cardiologist should perform or supervise an adequate number of cases annually, and the results must compare favorably with national experience. The cardiologist must keep himself up to date of new trends and progress in the field through scientific reading and attendance of meetings. Interventional pediatric cardiology has grown remarkably over the last two decades. Catheter based interventional procedures have become the treatment of choice for many cardiac lesions, and these procedures serve as alternatives or adjuncts to surgical treatment for many other relevant conditions. Keeping with the pace of development worldwide, catheter based interventional procedures are making good progress in Bangladesh as well.

A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation

Cytokines have always been of great interest due to their vast potential and participation in the progression and pathogenesis of various ailments. Interleukin-32 (IL-32) is a recently identified cytokine, whose gene is located on human chromosome 16 p13.3, with eight exons and six splice variants (IL-32α to IL-32ζ). IL-32α, the most abundant form, is secreted by different types of cells including T cells, natural killer (NK) cells, monocytes, endothelial cells and epithelial cells. It acts as a preferential mediator and effector of abnormal immune responses to multiple inflammatory and auto immune diseases including rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), etc. It was found to stimulate the induction of various chemokines, pro-inflammatory cytokines including IL-1β, IL-6, IL-8, TNF-α and macrophage inflammatory protein-2 (MIP-2). Hence, IL-32 mediates the crucial interplay among immune system and body cells during pathogenesis of various insults. The aim of the present effort is to summarize the role, mechanism of pathogenesis and potential therapeutic applications of IL-32 in different systemic infections and diseased conditions.

Clinical and pathological features of Nerium oleander extract toxicosis in wistar rats

BACKGROUND

Nerium oleander has been widely studied for medicinal purposes for variety of maladies. N. oleander has also been reported having noxious effects because of its number of components that may show signs of toxicity by inhibiting plasma lemma Na+, K+-ATPase. The present study was performed to scrutinize the toxic effect of N. oleander leaves extract and its clinical and pathological features in wistar rats.

RESULTS

Hematological analysis showed significant variations in RBCs count (P = 0.01), Hb (P = 0.001), Hct (P = 0.0003), MCV (P = 0.013), lymphocyte count (P = 0.015), neutrophil count (P = 0.003), monocyte count (P = 0.012) and eosinophil count (P = 0.006). Histopathological studies have shown that in T1 group noticeable infiltration of inflammatory cells was found with low level of vascular damage. In T2 group, increased proportion of binucleated and inflammatory cells, hepatic necrosis, widening of sinusoidal spaces and mild level of vascular damage was observed.

CONCLUSION

Taken together these findings we can conclude that N. oleander leaves extract significantly affects on experimental animals due to its toxicity. Efforts must be exerted to purify different chemical components from extract with no inflammation as this plant is utilized in folk medicine with narrow therapeutic indices.

Impact of laccase enzyme inducers on solid waste compost maturity and stability

The influence of inducers of laccase produced by Pleurotus ostreatus-P1 on the physicochemical properties of solid waste compost was investigated. In order to examine the degree of humification and time period for maturity and stability of compost, three different treatments (T: laccase; T1: laccase+CuSO4; and T2: laccase+CuSO4+CaCl2) were inoculated on solid waste in the initial stage of the composting process. During the composting process, the carbon nitrogen ratio (C/N), nitrate ([Formula: see text]), ammonium nitrogen ([Formula: see text]), cation exchange capacity (CEC), humic acid (HA) and fulvic acid (FA) humification rate (HR), Humification Index (HI), and degree of polymerization (DP) were assessed for the evaluation of compost maturity and stability, and it was found that T2 treatment C/N, CEC, and HI was greater, 46.8%, 37.2%, and 38.46%, respectively, than T at the end of the maturation phase. Optimum degree of maturity was also appraised by the Germination Index, 98.25% was attained by T2, whereas 88.65% and 71.23% by T1 and T, respectively. Significant Pearson correlation was also found between compost characteristics such as C/N, CEC, HA, FA, DP, HI, and HR. In addition, also obstinate the mineralization's of nitrogen under laboratory incubation, using soil amended by 50 and 100 kg-N/ha and examined an increasing trend in nitrogen mineralization with the application rate. Moreover, it was concluded that the laccase inducers increase the disintegration and humification process during solid waste composting.

Abstract 2542: Sipuleucel-T-induced immune response against secondary cancer antigens is associated with improved overall survival

Introduction and Objective: Tumor cell death in response to immunotherapy may lead to the release of secondary (non-targeted) cancer antigens that prime subsequent immune responses (antigen spread) 1. This may contribute to tumor control and reveal post-treatment biomarkers of clinical outcome. Sipuleucel-T, an immunotherapy targeted towards the prostate-specific antigen, prostatic acid phosphatase, is approved in the US and EU for treatment of asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer. We evaluated: (i) antigen spread after sipuleucel-T treatment, based on IgG antibody responses against secondary cancer antigens, and (ii) association of such IgG responses with overall survival (OS).

Methods: ProtoArray®, an unbiased protein microarray platform, was used to characterize the spectrum of serum IgG responses after treatment. IgG responses against secondary antigens were confirmed using an independent platform, Luminex®, xMAP®. Pre- and post- treatment sera from two clinical trials of sipuleucel-T were analyzed: IMPACT 2 (double-blind, placebo-controlled, phase 3, NCT00065442) and ProACT (open-label, phase 2, NCT00715078). The correlations between IgG responses (≥ 2 fold elevation post-treatment) and OS were assessed in IMPACT using a Cox regression model, adjusted for baseline PSA, LDH, bone lesions, Gleason score, and prior bisphosphonate use.

Results: Serum IgG responses (p&lt;10-3) towards several secondary cancer antigens (PSA, hK2/KLK2, K-Ras, E-Ras, and LGALS8/PCTA-1) were observed after treatment with sipuleucel-T in IMPACT as well as ProACT. Across trials, the frequency of patients with IgG responses after sipuleucel-T treatment was: ≥25% for PSA, ≥33% for hK2, ≥36% for K-Ras, ≥39% for E-Ras, ≥24% for LGALS8. These IgG responses were observed as early as 2 weeks and up to 6 months after treatment with sipuleucel-T. Control arm patients in IMPACT did not show such responses (p&gt;0.01). In the sipuleucel-T arm of IMPACT (N=140), an IgG response to PSA ≈2 weeks after treatment was positively correlated with increased OS, compared to patients with no IgG response to PSA (Cox p&lt;0.01, HR≈0.41 [95% CI=0.22-0.78]). Other IgG responses (such as those against E-Ras and hK2) at ≈2 or ≈10 weeks after treatment, also showed trends towards improved OS.

Conclusions: Sipuleucel-T elicited IgG responses against multiple cancer antigens. Sipuleucel-T- induced IgG response against PSA was positively correlated with improved OS. These data enhance our understanding of sipuleucel-T's mechanism of action, and may help to identify pharmacodynamic biomarkers of clinical outcome. The methods and results presented here may also help in the characterization of antigen spread and pharmacodynamic biomarkers after treatment with other cancer immunotherapies.

1. Ribas A, et al. Trends Immunol. 24:58-61 (2003)

2. Kantoff PW, et al. N Engl J Med. 363:411-22 (2010)

Citation Format: Debraj GuhaThakurta, Li-Qun Fan, Tuyen Vu, Francis Stewart, Philip Kantoff, Eric Small, Celeste Higano, Thomas Gardner, Nadeem Sheikh, James Trager. Sipuleucel-T-induced immune response against secondary cancer antigens is associated with improved overall survival. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2542. doi:10.1158/1538-7445.AM2014-2542

Abstract 2937: Localization of sipuleucel-T- expanded T cell clones into tumors of treated prostate cancer patients

Sipuleucel-T is an FDA-approved autologous cellular therapy demonstrated to prolong overall survival in subjects with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC). Sipuleucel-T is generated by culturing patients' own peripheral blood mononuclear cells (PBMC) with a fusion protein of prostatic acid phosphatase and granulocyte macrophage colony stimulating factor. While antigen presenting cells take up this antigen and can prime antigen specific T cells in vivo, the majority of the cells in the sipuleucel-T product are in fact T cells. Moreover, antigen-specific T cells in the product become activated during production of sipuleucel-T, particularly for the 2nd and 3rd infusions.

To examine whether T cells contained in sipuleucel-T might be homing to the site of the tumor, we used a next-generation sequencing-based method to assess T cell repertoire diversity in the blood, sipuleucel-T product, and resected tissues of patients participating in a neoadjuvant study of sipuleucel-T treatment (P07-1; NCT00715104). In this trial, patients with localized prostate cancer received sipuleucel-T prior to undergoing radical prostatectomy (RP). DNA extracted from the different samples was amplified using a multiplex PCR assay to amplify the CDR3 region of the T cell receptor spanning the variable region formed by the junction of the V, D and J segments and their associated non-templated insertions. Sequence reads were used to quantitate absolute TCR frequencies using standardized clonotype determination algorithms. We found that a subset of T cell clones was enriched in the generation of sipuleucel-T. We also found that T cell clones were expanded in patient blood after each successive infusion. When we examined the T cell clonotypes in the prostate tissues resected after sipuleucel-T treatment, we found that there were T cell clones in the prostate in common with the sipuleucel-T product. Interestingly a number of the clones present in the pre-treatment blood were reduced or lost in the blood by the second and third infusion but were present in the post-treatment prostate tissue, consistent with trafficking of the T cell clones from the peripheral circulation. These results indicate that ex vivo production of sipuleucel-T induces the expansion of certain T cell clones that are ultimately present in the prostates of patients treated prior to RP. Sipuleucel-T may therefore also function as an adoptive T cell therapy.

Citation Format: Lawrence Fong, Todd DeVries, Jason Cham, Li Zhang, Mark Frohlich, James Trager, Nadeem Sheikh. Localization of sipuleucel-T- expanded T cell clones into tumors of treated prostate cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2937. doi:10.1158/1538-7445.AM2014-2937